Clinical Core

Information

  • Research Project
  • 10237342
  • ApplicationId
    10237342
  • Core Project Number
    P30DK089507
  • Full Project Number
    5P30DK089507-12
  • Serial Number
    089507
  • FOA Number
    RFA-DK-19-003
  • Sub Project Id
    8130
  • Project Start Date
    7/6/2010 - 13 years ago
  • Project End Date
    5/31/2025 - a year from now
  • Program Officer Name
  • Budget Start Date
    6/1/2021 - 2 years ago
  • Budget End Date
    5/31/2022 - a year ago
  • Fiscal Year
    2021
  • Support Year
    12
  • Suffix
  • Award Notice Date
    8/25/2021 - 2 years ago

Clinical Core

PROJECT SUMMARY/ABSTRACT The Clinical Core provides both services and expertise and has a strong training component for cystic fibrosis (CF) research. The services focus on regulatory support, and study design and conduct support. We serve as a local, National and International resource to collaborators for advanced clinical trial design and conduct, biostatistical and epidemiologic methods and comparative effect research methods including cost-effectiveness analysis. The Core supports the central aims of the UW Cystic Fibrosis Research and Translation Center (CFRTC): to use highly effective modulator therapy (HEMT) initiation to discover novel aspects of cystic fibrosis (CF) pathophysiology, define the clinical manifestations and best treatment approaches for the ?new? disease that CF will become, and perform basic and translational research on disease aspects that persist despite HEMT. Further, the CC fosters collaboration across the CFRTC biomedical cores to enhance translational research through the sharing of existing and development of expanded human and bacterial repositories linked to clinical databases that enable development of improved assays and clinical outcome measures. We are well positioned to continue to advance novel therapeutics through the drug development pipeline and transition to major studies in CF that focus on improving our understanding of the disease in the setting of advancing therapeutics ? specifically HEMT that will forever change the clinical landscape in CF.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    P30
  • Administering IC
    DK
  • Application Type
    5
  • Direct Cost Amount
    194180
  • Indirect Cost Amount
    41496
  • Total Cost
  • Sub Project Total Cost
    235676
  • ARRA Funded
    False
  • CFDA Code
  • Ed Inst. Type
  • Funding ICs
    NIDDK:235676\
  • Funding Mechanism
    RESEARCH CENTERS
  • Study Section
    ZDK1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    SEATTLE CHILDREN'S HOSPITAL
  • Organization Department
  • Organization DUNS
    048682157
  • Organization City
    SEATTLE
  • Organization State
    WA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    981053901
  • Organization District
    UNITED STATES